Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 6, Issue 3, 2006, Pages 191-207

  De Meyer, S F ^a   Vanhoorelbeke, K ^a   Ulrichts, H ^a   Staelens, S ^a   Feys, H B ^a   Salles, I ^a   Fontayne, A ^a   Deckmyn, Hans ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anti thrombotic drug; Antibody; GPIb IX V; GPIIb IIIa; Platelet; Von Willebrand factor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; CRC 64; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRAMON; GLYCOPROTEIN IB; HEPARIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONAFRAM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E5; MONOCLONAL ANTIBODY 16N7C2; MONOCLONAL ANTIBODY 6B4; MONOCLONAL ANTIBODY AP 2; MONOCLONAL ANTIBODY C4G1; MONOCLONAL ANTIBODY LJ CP8; THROMBOCYTE RECEPTOR; THROMBOXANE A2; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; YM 207; YM 337;

ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING DISORDER; BLEEDING TENDENCY; BLOOD VESSEL WALL; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EXPERIMENTAL MODEL; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW; SUBENDOTHELIUM; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOGENESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; FIBRINOLYTIC AGENTS; HUMANS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; VON WILLEBRAND FACTOR;

EID: 33748629116     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152906778249536     Document Type: Review

References (152)

1. Ulrichts, H., Vanhoorelbeke, K., Van de walle, G., Katsutani, S., De Meyer, S., Staelens, S., and Deckmyn, H. New approaches for antithrombotic antiplatelet therapies. Curr. Med. Chem, 2004, 3, 552-561.
2. Vanhoorelbeke, K., Ulrichts, H., Schoolmeester, A., and Deckmyn, H. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr. Drug Targets Cardiovasc. Haematol. Disord, 2003, 3, 125-140.
3. Goto, S. Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents. Curr. Vasc. Pharmacol., 2004, 2, 23-32.
4. Huang, F. and Hong, E. Platelet glycoprotein IIb/IIIa inhibition and its clinical use. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2004, 2, 187-196.
5. Wagner, C.L., Mascelli, M.A., Neblock, D.S., Weisman, H.F., Coller, B.S., and Jordan, R.E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood, 1996, 88, 907-914.
6. Phillips, D.R., Charo, I.F., Parise, L.V., and Fitzgerald, L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood, 1988, 71, 831-843.
7. Lefkovits, J., Plow, E.F., and Topol, E.J. Platelet glycoprotein IIb/ IIIa receptors in cardiovascular medicine. N. Engl. J. Med., 1995, 332, 1553-1559.
8. Li, R., Mitra, N., Gratkowski, H., Vilaire, G., Litvinov, R., Nagasami, C., Weisel, J.W., Lear, J.D., DeGrado, W.F., and Bennett, J.S. Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science, 2003, 300, 795-798.
9. Xiao, T., Takagi, J., Coller, B.S., Wang, J.H., and Springer, T.A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature, 2004, 432, 59-67.
10. Legrand, C., Dubernard, V., and Nurden, A.T. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood, 1989, 73, 1226-1234.
11. Hodivala-Dilke, K.M., McHugh, K.P., Tsakiris, D.A., Rayburn, H., Crowley, D., Ullman-Cullere, M., Ross, F.P., Coller, B.S., Teitelbaum, S., and Hynes, R.O. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest., 1999, 103, 229-238.
12. Smyth, S.S., Reis, E.D., Vaananen, H., Zhang, W., and Coller, B.S. Variable protection of beta 3-integrin - deficient mice from thrombosis initiated by different mechanisms. Blood, 2001, 98, 1055-1062.
13. Takami, H., Nichols, W.L., Kaese, S.E., Miller, R.S., Katzmann, J.A., and Bowie, E.J.W. Monoclonal-Antibodies Against Porcine Platelet Membrane Glycoprotein-Ib and Glycoprotein-IIb/IIIa. Blood, 1988, 72, 1740-1747.
14. Nakatanl, S., Hato, T., Minamoto, Y., and Fujita, S. Differential inhibition of fibrinogen binding to agonist- and RGDS peptide-activated states of GPIIb-IIIa by an anti-GPIIIa monoclonal antibody, PMA5. Thromb. Haemost., 1996, 76, 1030-1037.
15. Thomas, S., Metcalfe, P., Goodall, A.H., and Gray, E. Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibalpha inhibit platelet dependent thrombin generation by different mechanisms. Thromb. Haemost., 2000, 84, 98-103.
16. Peerschke, E.I.B. and Coller, B.S. A Murine Monoclonal-Antibody That Blocks Fibrinogen Binding to Normal Platelets Also Inhibits Fibrinogen Interactions with Chymotrypsin-Treated Platelets. Blood, 1984, 64, 59-63.
17. Kasirer-Friede, A., Legrand, C., and Frojmovic, M.M. Complementary roles for fibrin(ogen), thrombospondin and vWF in mediating shear-dependent aggregation of platelets stimulated at threshold thrombin concentrations. Thromb. Haemost., 2001, 86, 653-659.
18. Lombardo, V.T., Hodson, E., Roberts, J.R., Kunicki, T.J., Zimmerman, T.S., and Ruggeri, Z.M. Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody. J. Clin. Invest., 1985, 76, 1950-1958.
19. McEver, R.P., Baenziger, N.L., and Majerus, P.W. Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody. J. Clin. Invest., 1980, 66, 1311-1318.
20. Montgomery, R.R., Kunicki, T.J., Taves, C., Pidard, D., and Corcoran, M. Diagnosis of Bernard-Soulier Syndrome and Glanzmanns Thrombasthenia with A Monoclonal Assay on Whole-Blood. J. Clin. Invest., 1983, 71, 385-389.
21. Hanson, S.R., Pareti, F.I., Ruggeri, Z.M., Marzec, U.M., Kunicki, T.J., Montgomery, R.R., Zimmerman, T.S., and Harker, L.A. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J. Clin. Invest., 1988, 81, 149-158.
22. Torem, S., Schneider, P.A., and Hanson, S.R. Monoclonal anti-body-induced inhibition of platelet function: effects on hemostasis and vascular graft thrombosis in baboons. J. Vasc. Surg., 1988, 7, 172-180.
23. Krupski, W.C., Bass, A., Kelly, A.B., Ruggeri, Z.M., Harker, L.A., and Hanson, S.R. Interruption of vascular thrombosis by bolus anti-platelet glycoprotein IIb/IIIa monoclonal antibodies in baboons. J. Vasc. Surg., 1993, 17, 294-303.
24. Deckmyn, H., Stanssens, P., Hoet, B., Declerck, P.J., Lauwereys, M., Gansemans, Y., Tornai, I., and Vermylen, J. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/ IIIa function. Br. J. Haematol., 1994, 87, 562-571.
25. Kotze, H.F., Badenhorst, P.N., Lamprecht, S., Meiring, M., van, W., V, Nuyts, K., Stassen, J.M., Vermylen, J., and Deckmyn, H. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Thromb. Haemost., 1995, 74, 751-757.
26. Wu, D., Meiring, M., Kotze, H.F., Deckmyn, H., and Cauwenberghs, N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 323-328.
27. Coller, B.S., Peerschke, E.I., Scudder, L.E., and Sullivan, C.A. A Murine Monoclonal-Antibody That Completely Blocks the Binding of Fibrinogen to Platelets Produces A Thrombasthenic-Like State in Normal Platelets and Binds to Glycoproteins-Iib and Or Glycoprotein-Iiia. J. Clin. Invest., 1983, 72, 325-338.
28. Folts, J.D., Gallagher, K., and Rowe, G.G. Blood-Flow Reductions in Stenosed Canine Coronary-Arteries - Vasospasm Or Platelet-Aggregation. Circulation, 1982, 65, 248-255.
29. Coller, B.S., Folts, J.D., Scudder, L.E., and Smith, S.R. Anti-thrombotic effect of a monoclonal antibody to the platelet glyco-protein IIb/IIIa receptor in an experimental animal model. Blood, 1986, 68, 783-786.
30. Coller, B.S. and Scudder, L.E. Inhibition of Dog Platelet (P) Function Invivo by Intravenous-Infusion of F(Ab')2 Fragments of A Monoclonal-Antibody (Mab) to Platelet-Gpiib/Iiia. Thromb. Haemost., 1985, 54, 277.
31. Coller, B.S., Folts, J.D., Smith, S.R., Scudder, L.E., and Jordan, R. Abolition of Invivo Platelet Thrombus Formation in Primates with Monoclonal-Antibodies to the Platelet Gpiib-Iiia Receptor - Correlation with Bleeding-Time, Platelet-Aggregation, and Blockade of Gpiib-Iiia Receptors. Circulation, 1989, 80, 1766-1774.
32. Coller, B.S., Scudder, L.E., Beer, J., Gold, H.K., Folts, J.D., Cavagnaro, J., Jordan, R., Wagner, C., Iuliucci, J., Knight, D., Ghrayeb, J., Smith, C., Weisman, H.F., and Berger, H. Monoclonal-Antibodies to Platelet Glycoprotein Iib/Iiia As Antithrombotic Agents. Ann. N. Y. Acad. Sci., 1991, 614, 193-213.
33. Coller, B.S. Blockade of Platelet Gpiib/Iiia Receptors As An Antithrombotic Strategy. Circulation, 1995, 92, 2373-2380.
34. Yasuda, T., Gold, H.K., Fallon, J.T., Leinbach, R.C., Guerrero, J.L., Scudder, L.E., Kanke, M., Shealy, D., Ross, M.J., Collen, D., and Coller, B.S. Monoclonal-Antibody Against the Platelet Glyco-protein (Gp) Iib/Iiia Receptor Prevents Coronary-Artery Reocclusion After Reperfusion with Recombinant Tissue-Type Plasminogen-Activator in Dogs. J. Clin. Invest., 1988, 81, 1284-1291.
35. Gold, H.K., Coller, B.S., Yasuda, T., Saito, T., Fallon, J.T., Guerrero, J.L., Leinbach, R.C., Ziskind, A.A., and Collen, D. Rapid and Sustained Coronary-Artery Recanalization with Combined Bolus Injection of Recombinant Tissue-Type Plasminogen-Activator and Monoclonal Antiplatelet Gpiib/Iiia Antibody in A Canine Preparation. Circulation, 1988, 77, 670-677.
36. Yasuda, T., Gold, H.K., Leinbach, R.C., Saito, T., Guerrero, J.L., Jang, I.K., Holt, R., Fallon, J.T., and Collen, D. Lysis of Plasminogen Activator-Resistant Platelet-Rich Coronary-Artery Thrombus with Combined Bolus Injection of Recombinant Tissue-Type Plasminogen-Activator and Antiplatelet Gpiib/Iiia Antibody. J. Am. Coll. Cardiol., 1990, 16, 1728-1735.
37. Tcheng, J.E., Ellis, S.G., George, B.S., Kereiakes, D.J., Kleiman, N.S., Talley, J.D., Wang, A.L., Weisman, H.F., Califf, R.M., and Topol, E.J. Pharmacodynamics of Chimeric Glycoprotein Iib/Iiia Integrin Antiplatelet Antibody Fab 7E3 in High-Risk Coronary Angioplasty. Circulation, 1994, 90, 1757-1764.
38. Curtin, R. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments. Curr. Pharm. Des., 2004, 10, 1577-1585.
39. Topol, E.J., Ferguson, J.J., Weisman, H.F., Tcheng, J.E., Ellis, S.G., Kleiman, N.S., Ivanhoe, R.J., Wang, A.L., Miller, D.P., Anderson, K.M., and Califf, R.M. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA, 1997, 278, 479-484.
40. Kam, P.C. and Egan, M.K. Platelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments. Anesthesiology, 2002, 96, 1237-1249.
41. Curtis, B.R., Swyers, J., Divgi, A., McFarland, J.G., and Aster, R.H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood, 2002, 99, 2054-2059.
42. Bougie, D.W., Wilker, P.R., Wuitschick, E.D., Curtis, B.R., Malik, M., Levine, S., Lind, R.N., Pereira, J., and Aster, R.H. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood, 2002, 100, 2071-2076.
43. Christopoulos, C.G. Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors. Blood, 2003, 101, 1655.
44. Coller, B.S. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am. Heart J., 1999, 138, S1-S5.
45. Mazurov, A.V., Pevzner, D.V., Antonova, O.A., Byzova, T.V., Khaspekova, S.G., Semenov, A.V., Vlasik, T.N., Samko, A.N., Staroverov, I.I., and Ruda, M.Y. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets, 2002, 13, 465-477.
46. Mazurov, A.V., Pevzner, D.V., Khaspekova, S.G., Dudnik, O.A., Byzova, T.V., Vlasik, T.N., Bakharev, V.N., Pistsov, M.I., Staroverov, I.I., and Ruda, M.I. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa]. Ter. Arkh., 2001, 73, 66-73.
47. Byzova, T.V., Vlasik, T.N., and Mazurov, A.V. [Inhibition of platelet aggregation with monoclonal antibodies to the glycoprotein IIb-IIIa complex]. Biull. Eksp. Biol. Med., 1994, 118, 402-405.
48. Mazurov, A.V., Pevzner, D.V., Semenov, A.V., Antonova, O.A., Dudnik, O.A., Khaspekova, S.G., Vlasik, T.N., Samko, A.N., Staroverov, I.I., and Ruda, M.I. [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]. Kardiologiia., 2002, 42, 8-17.
49. Mazurov, A.V., Pevzner, D.V., Vlasik, T.N., Ruda, M.I.A. Anti-platelet effects of glycoproteins IIb-IIIa antagonist monafram]. Ross. Fiziol. Zh. Im I. M Sechenova, 2004, 90, 586-599.
50. Yano, S., Suzuki, K., Katoh, M., Sugita, Y., Kaku, S., Kawamura, K., and Masuho, Y. Epitopes and biological activities of two monoclonal antibodies to platelet integrin alpha IIb beta 3. J. Biochem. (Tokyo), 1994, 116, 778-786.
51. Kaku, S., Kawasaki, T., Sakai, Y., Taniuchi, Y., Yano, S., Suzuki, K., Terazaki, C., Kawamura, K., Masuho, Y., Satoh, N., and. Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys. Eur. J. Pharmacol., 1995, 279, 115-121.
52. Co, M.S., Yano, S., Hsu, R.K., Landolfi, N.F., Vasquez, M., Cole, M., Tso, J.T., Bringman, T., Laird, W., Hudson, D., and. A humanized antibody specific for the platelet integrin gpIIb/IIIa. J. Immunol., 1994, 152, 2968-2976.
53. Kaku, S., Yano, S., Kawasaki, T., Sakai, Y., Suzuki, K., Kawamura, K., Masuho, Y., Satoh, N., Takenaka, T., Landolfi, N.F., and Co, M.S. Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Gen. Pharmacol., 1996, 27, 435-439.
54. Suzuki, K., Sato, K., Kamohara, M., Kaku, S., Kawasaki, T., Yano, S., and Iizumi, Y. Comparative studies of a humanized anti-glycoprotein IIb/ IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties. Biol. Pharm. Bull., 2002, 25, 1006-1012.
55. Kaku, S., Umemura, K., Mizuno, A., Yano, S., Suzuki, K., Kawasaki, T., and Nakashima, M. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur. J. Pharmacol., 1998, 345, 185-192.
56. Kaku, S., Kawasaki, T., Hisamichi, N., Sakai, Y., Taniuchi, Y., Inagaki, O., Yano, S., Suzuki, K., Terazaki, C., Masuho, Y., Satoh, N., Takenaka, T., Yanagi, K., and Ohshima, N. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb. Haemost., 1996, 75, 679-684.
57. Suzuki, K., Sakai, Y., Hisamichi, N., Taniuchi, Y., Sato, K., Terazaki, C., Kaku, S., Kawasaki, T., Yano, S., Inagaki, O., and Masuho, Y. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. Eur. J. Pharmacol., 1997, 336, 169-176.
58. Harder, S., Kirchmaier, C.M., Krzywanek, H.J., Westrup, D., Bae, J.W., and Breddin, H.K. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation, 1999, 100, 1175-1181.
59. Graff, J., Klinkhardt, U., Westrup, D., Kirchmaier, C.M., Breddin, H.K., and Harder, S. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IlIa inhibitor YM337 and unfractionated heparin and aspirin in humans. Br. J. Clin. Pharmacol., 2003, 56, 321-326.
60. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med., 1994, 330, 956-961.
61. Topol, E.J., Califf, R.M., Weisman, H.F., Ellis, S.G., Tcheng, J.E., Worley, S., Ivanhoe, R., George, B.S., Fintel, D., Weston, M., and Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet, 1994, 343, 881-886.
62. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N. Engl. J. Med., 1997, 336, 1689-1696.
63. Lincoff, A.M., Tcheng, J.E., Califf, R.M., Kereiakes, D.J., Kelly, T.A., Timmis, G.C., Kleiman, N.S., Booth, J.E., Balog, C., Cabot, C.F., Anderson, K.M., Weisman, H.F., and Topol, E.J. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/ IIIa blockade. Circulation, 1999, 99, 1951-1958.
64. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997, 349, 1429-1435.
65. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet, 1998, 352, 87-92.
66. Topol, E.J., Mark, D.B., Lincoff, A.M., Cohen, E., Burton, J., Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C.F., Anderson, K.M., and Califf, R.M. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet, 1999, 354, 2019-2024.
67. Moliterno, D.J., Yakubov, S.J., DiBattiste, P.M., Herrmann, H.C., Stone, G.W., Macaya, C., Neumann, F.J., Ardissino, D., Bassand, J.P., Borzi, L., Yeung, A.C., Harris, K.A., Demopoulos, L.A., and Topol, E.J. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet, 2002, 360, 355-360.
68. Brener, S.J., Barr, L.A., Burchenal, J.E., Katz, S., George, B.S., Jones, A.A., Cohen, E.D., Gainey, P.C., White, H.J., Cheek, H.B., Moses, J.W., Moliterno, D.J., Effron, M.B., and Topol, E.J. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation, 1998, 98, 734-741.
69. Topol, E.J., Moliterno, D.J., Herrmann, H.C., Powers, E.R., Grines, C.L., Cohen, D.J., Cohen, E.A., Bertrand, M., Neumann, F.J., Stone, G.W., DiBattiste, P.M., and Demopoulos, L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med., 2001, 344, 1888-1894.
70. Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J.M., Morice, M.C., Maillard, L., Pansieri, M., Choussat, R., and Pinton, P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med., 2001, 344, 1895-1903.
71. Simoons, M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet, 2001, 357, 1915-1924.
72. Ottervanger, J.P., Armstrong, P., Barnathan, E.S., Boersma, E., Cooper, J.S., Ohman, E.M., James, S., Topol, E., Wallentin, L., and Simoons, M.L. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) Trial. Circulation, 2003, 107, 437-442.
73. Stone, G.W., Grines, C.L., Cox, D.A., Garcia, E., Tcheng, J.E., Griffin, J.J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J.D., Rutherford, B.D., and Lansky, A.J. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med., 2002, 346, 957-966.
74. Cauwenberghs, N., Vanhoorelbeke, K., Vauterin, S., and Deckmyn, H. Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor. Platelets, 2000, 11, 373-378.
75. Nurden, A.T. and Caen, J.P. Specific roles for platelet surface glycoproteins in platelet function. Nature, 1975, 255, 720-722.
76. Ruggeri, Z.M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best. Pract. Res. Clin. Haematol., 2001, 14, 257-279.
77. Foster, P.A., Fulcher, C.A., Marti, T., Titani, K., and Zimmerman, T.S. A Major Factor-Viii Binding Domain Resides Within the Amino-Terminal 272 Amino-Acid-Residues of Von Willebrand Factor. J. Biol. Chem., 1987, 262, 8443-8446.
78. Sadler, J.E. New Concepts in Von Willebrand Disease. Annu. Rev. Med., 2005, 56, 173-191.
79. Ramasamy, I. Inherited bleeding disorders: disorders of platelet adhesion and aggregation. Crit. Rev. Oncol. Hematol., 2004, 49, 1-35.
80. Bennett, M.R. and O'Sullivan, M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol. Ther., 2001, 91, 149-166.
81. Chesebro, J.H., Lam, J.Y., Badimon, L., and Fuster, V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am. J. Cardiol., 1987, 60, 10B-16B.
82. Harker, L.A. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am. J. Cardiol., 1987, 60, 20B-28B.
83. Rekhter, M.D., O'Brien, E., Shah, N., Schwartz, S.M., Simpson, J.B., and Gordon, D. The importance of thrombus organization and stellate cell phenotype in collagen I gene expression in human, coronary atherosclerotic and restenotic lesions. Cardiovasc. Res., 1996, 32, 496-502.
84. Zahger, D., Fishbein, M.C., Garfinkel, L.I., Shah, P.K., Forrester, J.S., Regnstrom, J., Yano, J., and Cercek, B. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation, 1995, 92, 1269-1273.
85. Matsuno, H., Kozawa, O., Niwa, M., and Uematsu, T. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation, 1997, 96, 1299-1304.
86. Matsuno, H., Kozawa, O., Niwa, M., Tanabe, K., Ichimaru, K., Takiguchi, Y., Yokota, M., Hayashi, H., and Uematsu, T. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb. Haemost., 1998, 79, 865-871.
87. Waissbluth, A., Ghigliotti, G., Abendschein, D.R., Eisenberg, P.R., and Schwartz, D. Aurintricarboxylic acid attenuates intimal thickening after balloon injury of the rabbit aorta. Thromb. Haemost., 2002, 88, 668-672.
88. Davis, J.A., Brown, A.T., Alshafie, T., Poirier, L.A., Cruz, C.P., Wang, Y., Eidt, J.F., and Moursi, M.M. Saratin (an inhibitor of platelet-collagen interaction) decreases platelet aggregation and homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a dose-dependent manner. Am. J. Surg., 2004, 188, 778-785.
89. Cruz, C.P., Eidt, J., Drouilhet, J., Brown, A.T., Wang, Y., Barnes, C.S., and Moursi, M.M. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J. Vasc. Surg., 2001, 34, 724-729.
90. Andrews, R.K. and Berndt, M.C. Snake venom modulators of platelet adhesion receptors and their ligands. Toxicon, 2000, 38, 775-791.
91. Chang, M.C., Lin, H.K., Peng, H.C., and Huang, T.F. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood, 1998, 91, 1582-1589.
92. Yeh, C.H., Chang, M.C., Peng, H.C., and Huang, T.F. Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. Br. J. Pharmacol., 2001, 132, 843-850.
93. Inbal, A., Gurevitz, O., Tamarin, I., Eskaraev, R., Chetrit, A., Novicov, I., Feldman, M., Varon, D., Eldar, M., and Loscalzo, J. Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: In vitro and ex vivo inhibition of platelet function. Blood, 1999, 94, 1693-1700.
94. McGhie, A.I., McNatt, J., Ezov, N., Cui, K., Mower, L.K., Hagay, Y., Buja, L.M., Garfinkel, L.I., Gorecki, M., and Willerson, J.T. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation, 1994, 90, 2976-2981.
95. Wells, D.S., Hensel, R., Loullis, C., Brophy, P., Mullin, M.E., Murray, E., and Ricca, G. Disposition of a novel recombinant antithrombotic agent, RG 12986, in cynomolgus monkeys. Drug Metab. Dispos., 1996, 24, 1102-1106.
96. Azzam, K., Garfinkel, L.I., Bal dit, S.C., Cisse, T.M., and Drouet, L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb. Haemost., 1995, 73, 318-323.
97. Bellinger, D.A., Nichols, T.C., Read, M.S., Reddick, R.L., Lamb, M.A., Brinkhous, K.M., Evatt, B.L., and Griggs, T.R. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc. Natl. Acad. Sci. USA, 1987, 84, 8100-8104.
98. Krupski, W.C., Bass, A., Cadroy, Y., Kelly, A.B., Harker, L.A., and Hanson, S.R. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates. Surgery, 1992, 112, 433-439.
99. Cadroy, Y., Hanson, S.R., Kelly, A.B., Marzec, U.M., Evatt, B.L., Kunicki, T.J., Montgomery, R.R., and Harker, L.A. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood, 1994, 83, 3218-3224.
100. Cisse-Thiam, M., Girma, J.P., Meyer, D., and Drouet, L. [Inhibition of thrombus formation by anti-Willebrand monoclonal antibodies in the guinea pig]. Dakar Med., 1999, 44, 45-48.
101. Kageyama, S., Yamamoto, H., Nagano, M., Arisaka, H., Kayahara, T., and Yoshimoto, R. Anti-thrombotic effects and bleeding risk of AJv W-2, a monoclonal antibody against human von Willebrand factor. Br. J. Pharmacol., 1997, 122, 165-171.
102. Yamamoto, H., Vreys, I., Stassen, J.M., Yoshimoto, R., Vermylen, J., and Hoylaerts, M.F. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb. Haemost., 1998, 79, 202-210.
103. Kageyama, S., Yamamoto, H., Nakazawa, H., and Yoshimoto, R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb. Res., 2001, 101, 395-404.
104. Kageyama, S., Yamamoto, H., Nakazawa, H., Matsushita, J., Kouyama, T., Gonsho, A., Ikeda, Y., and Yoshimoto, R. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 187-192.
105. Kageyama, S., Matsushita, J., and Yamamoto, H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur. J. Pharmacol., 2002, 443, 143-149.
106. Machin, S.J., Clarke, C., Ikemura, O., Kageyama, S., Mackie, I.J., Talbot, J.A., Ikeda, Y., and Gyotoku, Y. A humanized monoclonal antibody against VWF A1 domain inhibits VWF:RiC of activity and platelet adhesion in human volunteers. J. Thromb. Haemost., 2003, 1 (Supplement 1), OC328.
107. Lopez, J.A. The platelet glycoprotein Ib-IX complex. Blood Coagul. Fibrinolysis, 1994, 5, 97-119.
108. Lopez, J.A., Chung, D.W., Fujikawa, K., Hagen, F.S., Davie, E.W., and Roth, G.J. The Alpha and Beta Chains of Human-Platelet Glycoprotein-Ib Are Both Transmembrane Proteins Containing A Leucine-Rich Amino-Acid Sequence. Proc. Natl. Acad. Sci. USA, 1988, 85, 2135-2139.
109. Hickey, M.J., Williams, S.A., and Roth, G.J. Human-Platelet Glycoprotein-Ix - An Adhesive Prototype of Leucine-Rich Glycoproteins with Flank-Center-Flank Structures. Proc. Natl. Acad. Sci. USA, 1989, 86, 6773-6777.
110. Hickey, M.J., Hagen, F.S., Yagi, M., and Roth, G.J. Human Platelet Glycoprotein-V - Characterization of the Polypeptide and the Related Ib-V-Ix Receptor System of Adhesive, Leucine-Rich Glycoproteins. Proc. Natl. Acad. Sci. USA, 1993, 90, 8327-8331.
111. Du, X.P., Beutler, L., Ruan, C.G., Castaldi, P.A., and Berndt, M.C. Glycoprotein-Ib and Glycoprotein-Ix Are Fully Complexed in the Intact Platelet Membrane. Blood, 1987, 69, 1524-1527.
112. Handa, M., Titani, K., Holland, L.Z., Roberts, J.R., and Ruggeri, Z.M. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J. Biol. Chem., 1986, 261, 12579-12585.
113. Berndt, M.C., Shen, Y., Dopheide, S.M. Gardiner, E.E., and Andrews, R.K. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb. Haemost., 2001, 86, 178-188.
114. Cauwenberghs, N., Vanhoorelbeke, K., Vauterin, S., Westra, D.F., Romo, G., Huizinga, E.G., Lopez, J.A., Berndt, M.C., Harsfalvi, J., and Deckmyn, H. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood, 2001, 98, 652-660.
115. Shimizu, A., Matsushita, T., Kondo, T., Inden, Y., Kojima, T., Saito, H., and Hirai, M. Identification of the amino acid residues of the platelet glycoprotein Ib (GPIb) essential for the von Willebrand factor binding by clustered charged-to-alanine scanning mutagenesis. J. Biol. Chem., 2004, 279, 16285-16294.
116. Dong, J.F., Li, C.Q., and Lopez, J.A. Tyrosine Sulfation of the Glycoprotein Ib-Ix Complex - Identification of Sulfated Residues and Effect on Ligand-Binding. Biochemistry, 1994, 33, 13946-13953.
117. Marchese, P., Murata, M., Mazzucato, M., Pradella, P., De Marco, L., Ware, J., and Ruggeri, Z.M. Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. J. Biol. Chem., 1995, 270, 9571-9578.
118. Murata, M., Ware, J., and Ruggeri, Z.M. Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ib alpha demonstrating negatively charged residues involved in von Willebrand factor binding. J. Biol. Chem., 1991, 266, 15474-15480.
119. Ward, C.M., Andrews, R.K., Smith, A.L., and Berndt, M.C. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry, 1996, 35, 4929-4938.
120. Shen, Y., Dong Jf, J.F., Romo, G.M., Arceneaux, W., Aprico, A., Gardiner, E.E., Lopez, J.A., Berndt, M.C., and Andrews, R.K. Functional analysis of the C-terminal flanking sequence of platelet glycoprotein Ib alpha using canine-human chimeras. Blood, 2002, 99, 145-150.
121. Dong, J., Schade, A.J., Romo, G.M., Andrews, R.K., Gao, S., McIntire, L.V., and Lopez, J.A. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J. Biol. Chem., 2000, 275, 27663-27670.
122. Moriki, T., Murata, M., Kitaguchi, T., Anbo, H., Handa, M., Watanabe, K., Takahashi, H., and Ikeda, Y. Expression and functional characterization of an abnormal platelet membrane glycoprotein Ib alpha (Met239 → Val) reported in patients with platelet-type von Willebrand disease. Blood, 1997, 90, 698-705.
123. Afshar-Kharghan, V., Gineys, G., Schade, A.J., Sun, L., Li, C.Q., McIntire, L.V., Dong, J.F., and Lopez, J.A. Necessity of conserved asparagine residues in the leucine-rich repeats of platelet glycoprotein Ib alpha for the proper conformation and function of the ligand-binding region. Biochemistry, 2000, 39, 3384-3391.
124. Shen, Y., Romo, G.M., Dong, J.F., Schade, A., McIntire, L.V., Kenny, D., Whisstock, J.C., Berndt, M.C., Lopez, J.A., and Andrews, R.K. Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood, 2000, 95, 903-910.
125. Uff, S., Clemetson, J.M., Harrison, T., Clemetson, K.J., and Emsley, J. Crystal Structure of the Platelet Glycoprotein Ibalpha N-terminal Domain Reveals an Unmasking Mechanism for Receptor Activation. J. Biol. Chem., 2002, 277, 35657-35663.
126. Huizinga, E.G., Tsuji, S., Romijn, R.A., Schiphorst, M.E., de Groot, P.G., Sixma, J.J., and Gros, P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science, 2002, 297, 1176-1179.
127. Dumas, J.J., Kumar, R., McDonagh, T., Sullivan, F., Stahl, M.L., Somers, W.S., and Mosyak, L. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J. Biol. Chem., 2004, 279, 23327-23334.
128. Takami, N. and Tamai, Y. Bleeding time. Jpn. J. Clin. Pathol., 1992, 40, 266-271.
129. Kupinski, J.M. and Miller, J.L. Identification of Receptors for Fibrinogen and Vonwillebrand-Factor Mediating Aggregation in Guinea-Pig Platelets. Thromb. Res., 1986, 43, 335-344.
130. Kupinski, J.M. and Miller, J.L. Synthesis by Guinea-Pig Megakaryocytes of Platelet Glycoprotein Receptors for Fibrinogen and Vonwillebrand-Factor. Thromb. Res, 1986, 43, 345-352.
131. Becker, B.H. and Miller, J.L. Effects of an antiplatelet glycoprotein Ib antibody on hemostatic function in the guinea pig. Blood, 1989, 74, 690-694.
132. Miller, J.L., Thiam-Cisse, M., and Drouet, L.O. Reduction in thrombus formation by PG-1 F(ab')2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody. Arterioscler. Thromb., 1991, 11, 1231-1236.
133. Cauwenberghs, N., Meiring, M., Vauterin, S., Van, W., V, Lamprecht, S., Roodt, J.P., Novak, L., Harsfalvi, J., Deckmyn, H., and Kotze, H.F. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1347-1353.
134. Bernardi, M.M., Califf, R.M., Kleiman, N., Ellis, S.G., and Topol, E.J. Lack of Usefulness of Prolonged Bleeding Times in Predicting Hemorrhagic Events in Patients Receiving the 7E3 Glycoprotein Iib/Iiia Platelet Antibody. Am. J. Cardiol, 1993, 72, 1121-1125.
135. Ribba, A,S., Loisel, I., Lavergne, J.M., Juhan-Vague, I., Obert, B., Cherel, G., Meyer, D., and Girma, J.P. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb. Haemost., 2001, 86, 848-854.
136. Vanhoorelbeke, K. and Deckmyn, H. The role of vWF-collagen interaction in acute platelet thrombus formation. Drugs of the Future, 2003, 28, 61-67.
137. Connolly, T.M., Jacobs, J.W., and Condra, C. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. I. Identification, isolation, and characterization. J. Biol. Chem., 1992, 267, 6893-6898.
138. Keller, P.M., Schultz, L.D., Condra, C., Karczewski, J., and Connolly, T.M. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. II. Cloning of the cDNA and expression. J. Biol. Chem., 1992, 267, 6899-6904.
139. van Zanten, G.H., Connolly, T.M., Schiphorst, M.E., de Graaf, S., Slootweg, P.J., and Sixma, J.J. Recombinant leech antiplatelet protein specifically blocks platelet deposition on collagen surfaces under flow conditions. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1424-1431.
140. Depraetere, H., Kerekes, A., and Deckmyn, H. The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and alpha2beta1 (GPIa/IIa)-I-domain binding to collagen in a different manner. Thromb. Haemost., 1999, 82, 1160-1163.
141. Schaffer, L.W., Davidson, J.T., Siegl, P.K., Gould, R.J., Nutt, R.F., Brady, S.F., and Connolly, T.M. Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons. Arterioscler. Thromb., 1993, 13, 1593-1601.
142. Deckmyn, H., Stassen, J.M., Vreys, I., Van Houtte, E., Sawyer, R.T., and Vermylen, J. Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. Blood, 1995, 85, 712-719.
143. Harsfalvi, J., Stassen, J.M., Hoylaerts, M.F., Van Houtte, E., Sawyer, R.T., Vermylen, J., and Deckmyn, H. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood, 1995, 85, 705-711.
144. Barnes, C.S., Krafft, B., Frech, M., Hofmann, U.R., Papendieck, A., Dahlems, U., Gellissen, G., and Hoylaerts, M.F. Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin. Thromb. Hemost., 2001, 27, 337-348.
145. Southern, F., Eidt, J., Drouilhet, J., Mukunyadzi, P., Williams, D.K., Cruz, C., Wang, Y.F., Poirier, L.A., Brown, A.T., and Moursi, M.M. Increasing levels of dietary homocystine with carotid endarterectomy produced proportionate increases in plasma homocysteine and intimal hyperplasia. Atherosclerosis, 2001, 158, 129-138.
146. Vilahur, G., Duran, X., Juan-Babot, O., Casani, L., and Badimon, L. Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb. Haemost., 2004, 92, 191-200.
147. Hoylaerts, M.F., Yamamoto, H., Nuyts, K., Vreys, I., Deckmyn, H., and Vermylen, J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem. J., 1997, 324(Pt 1), 185-191.
148. Vanhoorelbeke, K., Depraetere, H., Romijn, R.A.P., Huizinga, E.G., De Maeyer, M., and Deckmyn, H. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal Anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J. Biol. Chem., 2003, 278, 37815-37821.
149. Wu, D., Vanhoorelbeke, K., Cauwenberghs, N., Meiring, M., Depraetere, H., Kotze, H.F., and Deckmyn, H. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood, 2002, 99, 3623-3628.
150. Sadler, J.E. Does VWF bind collagen after all? Blood, 2002, 99, 3491.
151. Bonnefoy, A., Yamamoto, H., Thys, C., Kito, M., Vermylen, J., and Hoylaerts, M.F. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood, 2003, 101, 1375-1383.
152. Vanhoorelbeke, K., Depraetere, H., Romijn, R.A.P., Huizinga, E.G., De Maeyer, M., and Deckmyn, H. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal Anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J. Biol. Chem., 2003, 278, 37815-37821.